Effects of hypoglycaemic agents on reducing surrogate metabolic parameters for the prevention of cardiovascular events and death in patients with type 2 diabetes: A systematic review and meta‐analysis
Authors' conclusion
In patients with type 2 diabetes, concomitant reductions in HbA1c and body weight might be more effective in preventing the risk of vascular events and mortality.
Study context
- Population
- Patients with T2D in large-scale trials of glucose-lowering therapies with >1000 patient-years of follow-up per randomized group (MEDLINE, EMBASE to June 30, 2022)
- Participants
- 227,220 patients34 trials
- Comparison
- Glucose-lowering therapies associated with weight gain vs weight loss, per 1% HbA1c reduction
- Outcome
- All-cause mortality
Methodological detailsrandom-effects model, meta-regression per 1% HbA1c reduction by body weight change
- Random-effects model
- Meta-regression per 1% HbA1c reduction by body weight change
Pooled result
As reported in the abstract
All-cause mortality per 1% HbA1c reduction
| Group | HR per 1% HbA1c reduction |
|---|---|
| Weight gain | 1.08 (95% CI 1.00-1.16) |
| Weight loss | 0.78 (95% CI 0.72-0.85) |
HR per 1% HbA1c reduction
Weight gain1.08 (95% CI 1.00-1.16)
Weight loss0.78 (95% CI 0.72-0.85)
- Mortality risk increased by 8% per 1% HbA1c reduction with therapies associated with weight gain
- HR 1.08, 95% CI 1.00-1.16
- Mortality risk reduced by 22% per 1% HbA1c reduction with therapies associated with weight loss
- HR 0.78, 95% CI 0.72-0.85
Further pooled results
- Concomitant HbA1c and body weight reductions associated with significantly lower risk of mortality and vascular events
Original publication
Effects of hypoglycaemic agents on reducing surrogate metabolic parameters for the prevention of cardiovascular events and death in patients with type 2 diabetes: A systematic review and meta‐analysis. Diabetes Obes Metab. Published 23 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →